Business Description
ISIN : US53220K5048
Share Class Description:
LGND: Ordinary Shares - Class BTotal Employee Number:
47Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.21 | |||||
Equity-to-Asset | 0.44 | |||||
Debt-to-Equity | 1.17 | |||||
Debt-to-EBITDA | 4.08 | |||||
Interest Coverage | 16.17 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 4.44 | |||||
Beneish M-Score | -4.28 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 4.3 | |||||
3-Year EBITDA Growth Rate | 22.5 | |||||
3-Year EPS without NRI Growth Rate | 19.3 | |||||
3-Year FCF Growth Rate | -35.9 | |||||
3-Year Book Growth Rate | 13.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 21.36 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 19.24 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 43.58 | |||||
9-Day RSI | 43.21 | |||||
14-Day RSI | 45.13 | |||||
3-1 Month Momentum % | 26.12 | |||||
6-1 Month Momentum % | 50.02 | |||||
12-1 Month Momentum % | 86.99 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 31.18 | |||||
Quick Ratio | 30.99 | |||||
Cash Ratio | 29.33 | |||||
Days Inventory | 284.44 | |||||
Days Sales Outstanding | 70.06 | |||||
Days Payable | 165.84 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.3 | |||||
Shareholder Yield % | -10.85 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 95.43 | |||||
Operating Margin % | 34.45 | |||||
Net Margin % | 67.88 | |||||
EBITDA Margin % | 95.36 | |||||
FCF Margin % | 41.22 | |||||
OCF Margin % | 45.33 | |||||
ROE % | 20.71 | |||||
ROA % | 12.8 | |||||
ROIC % | 11.2 | |||||
ROC (Joel Greenblatt) % | 503.12 | |||||
ROCE % | 16.31 | |||||
Years of Profitability over Past 10-Year | 6 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 30.43 | |||||
Forward PE Ratio | 30.72 | |||||
PE Ratio without NRI | 31.23 | |||||
Shiller PE Ratio | 48.43 | |||||
Price-to-Owner-Earnings | 25.83 | |||||
PEG Ratio | 7.44 | |||||
PS Ratio | 20.32 | |||||
PB Ratio | 5.86 | |||||
Price-to-Tangible-Book | 8.63 | |||||
Price-to-Free-Cash-Flow | 48.79 | |||||
Price-to-Operating-Cash-Flow | 44.41 | |||||
EV-to-EBIT | 22.25 | |||||
EV-to-Forward-EBIT | 35.32 | |||||
EV-to-EBITDA | 19.61 | |||||
EV-to-Forward-EBITDA | 35.32 | |||||
EV-to-Revenue | 18.7 | |||||
EV-to-Forward-Revenue | 19.33 | |||||
EV-to-FCF | 45.37 | |||||
Price-to-GF-Value | 1.52 | |||||
Price-to-Projected-FCF | 4.45 | |||||
Price-to-Median-PS-Value | 2 | |||||
Price-to-Graham-Number | 3.46 | |||||
| Price-to-Net-Current-Asset-Value | 23.73 | |||||
| Price-to-Net-Cash | 37.19 | |||||
Earnings Yield (Greenblatt) % | 4.49 | |||||
FCF Yield % | 2.11 | |||||
Forward Rate of Return (Yacktman) % | 15.57 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:LGND
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Ligand Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 290.542 | ||
| EPS (TTM) ($) | 9.35 | ||
| Beta | 1.4062 | ||
| 3-Year Sharpe Ratio | 1.27 | ||
| 3-Year Sortino Ratio | 2.99 | ||
| Volatility % | 43.67 | ||
| 14-Day RSI | 45.13 | ||
| 14-Day ATR ($) | 9.97608 | ||
| 20-Day SMA ($) | 290.76875 | ||
| 12-1 Month Momentum % | 86.99 | ||
| 52-Week Range ($) | 158.4 - 326.63 | ||
| Shares Outstanding (Mil) | 19.94 |
Piotroski F-Score Details
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ligand Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ligand Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-26 08:30 | In 183 days | ||
| Annual report for 2026 | 2027-02-26 | In 182 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-26 | In 182 days | ||
| Ligand Pharmaceuticals Investor Day | 2026-12-08 10:30 | In 103 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-06 08:30 | In 71 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 70 days | ||
| H.C. Wainwright 28th Annual Global Investment Conference | 2026-09-14 10:00 | In 18 days | ||
| Guidance call for 2026 | 2026-09-10 09:20 | In 14 days | ||
| Guidance call for 2026 | 2026-09-08 12:45 | In 12 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 08:30 | 302.57 (-0.88%) |
Ligand Pharmaceuticals Inc Frequently Asked Questions
Guru Commentaries on NAS:LGND
We have also been invested in Ligand since 2023, and it has been a multi-bagger over our holding period driven by a strong new product launch cycle. Our current royalty companies possess unique catalysts that we believe will unlock shareholder value in the future including new product cycles and litigation events.
The Healthcare sector was once again led by Ligand (LGND:NGM) and Madrigal (MDGL:NGS), indicating strong performance and confidence in Ligand's business model. The manager expresses optimism about Ligand's potential, particularly in the context of biopharmaceutical royalties and metabolic disorders, suggesting a positive outlook for future growth. This aligns with the broader strategy of targeting high-potential investments in the healthcare space.
Ligand Pharmaceuticals operates a unique business model as a royalty aggregator, requiring minimal capital for growth since its partners fund product development and commercialization expenses. Our investment thesis is centered on the successful launch of Ohtuvaryre for COPD and Filspari for nephropathy, both of which are expected to drive stronger-than-anticipated results. Ohtuvaryre has already emerged as one of the strongest pharmaceutical launches in recent years, and we anticipate both drugs reaching blockbuster status over time. We expect management to raise long-term financial targets during the upcoming analyst day, maintaining our $250 price target.
Press Release
Articles on Ligand Pharmaceuticals Inc
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
